{"entity":{"id":"cytospire-therapeutics","kind":"company","name":"Cytospire Therapeutics","aka":[],"tldr":"Cytospire Therapeutics makes antibodies that pull a particular family of immune cells, gamma delta T cells, onto cancer cells so they kill them. Its first medicine, for bowel, head and neck and lung cancers that carry the EGFR protein, was being prepared for its first human trial in 2026.","summary":"Cytospire Therapeutics is a London biotech developing multispecific antibodies that engage gamma delta T cells across their subtypes (pan-gamma delta T cell engagers) rather than the CD3 receptor used by most T cell engagers. Its lead programme, CYT X300, is intended for EGFR-positive solid tumours such as colorectal, head and neck and non-small cell lung cancers and had not entered human testing in May 2026. On 5 May 2026 the company announced an oversubscribed GBP 61 million (USD 83 million) Series A led by 4BIO Capital, with Servier Ventures, Sound Bioventures, British Business Bank, Criteria Bio Ventures, Modi Ventures, Medical Incubator Japan and Pathway Bioventures joining existing investors Abingworth and LifeArc Ventures. Natalie Mount is chief executive.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.cytospire.com/"},{"label":"GBP 61 million Series A, May 2026","url":"https://www.cytospire.com/cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell-engagers-into-clinical-trials-for-the-treatment-of-can/"},{"label":"BioPharma Dive: Cytospire raises USD 83M","url":"https://www.biopharmadive.com/news/cytospire-gamma-delta-t-cell-engager-series-a/819234/"}],"tags":[],"related":[],"cancers":["colorectal","head-and-neck","nsclc"],"sections":["immunotherapy"],"technologies":["t-cell-engager"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated. An earlier seed round led by Abingworth is mentioned in trade coverage but its date and amount were not found in a primary source, so the May 2026 Series A is the first announced financing on record here."],"hq":"London","country":"GB","companyType":"biotech","website":"https://www.cytospire.com/","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2026,"amountUsd":83000000,"source":"https://www.cytospire.com/cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell-engagers-into-clinical-trials-for-the-treatment-of-can/","note":"GBP 61 million; the release states the USD 83 million equivalent. Led by 4BIO Capital"}]},"route":"/companies/cytospire-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}]}}